Tags

Type your tag names separated by a space and hit enter

[Management of hyperphosphatemia ; phosphate-binder].
Clin Calcium. 2009 Feb; 19(2):205-12.CC

Abstract

Numerous experimental and clinical studies have recently addressed the underlying mechanisms in particular the marked increase in cardiovascular mortality in patients with CKD. Hyperphosphatemia is a major problem in these patients with advanced stage of CKD. Calcium carbonate became the most widely used phosphate binders ; however, increasing evidence now suggests that prolonged use of these agents increases the total body calcium load, induces adynamic bone, and potentially increases the risk of cardiovascular and soft tissue calcification. Sevelamer is the first phosphate-binding agent that is non-absorbed, calcium-free, and metal-free. To date, this agent has been shown to effectively control serum phosphorus levels in patients with CKD. It may also attenuate coronary and aortic calcification and has a number of other beneficial effects on lipid metabolism and inflammation among others.

Authors+Show Affiliations

The Jikei University School of Medicine, Department of Internal Medicine, Division of Nephrology and Hypertension.

Pub Type(s)

English Abstract
Journal Article
Review

Language

jpn

PubMed ID

19182360

Citation

Yokoyama, Keitaro. "[Management of Hyperphosphatemia ; Phosphate-binder]." Clinical Calcium, vol. 19, no. 2, 2009, pp. 205-12.
Yokoyama K. [Management of hyperphosphatemia ; phosphate-binder]. Clin Calcium. 2009;19(2):205-12.
Yokoyama, K. (2009). [Management of hyperphosphatemia ; phosphate-binder]. Clinical Calcium, 19(2), 205-12. https://doi.org/CliCa0902205212
Yokoyama K. [Management of Hyperphosphatemia ; Phosphate-binder]. Clin Calcium. 2009;19(2):205-12. PubMed PMID: 19182360.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Management of hyperphosphatemia ; phosphate-binder]. A1 - Yokoyama,Keitaro, PY - 2009/2/3/entrez PY - 2009/2/3/pubmed PY - 2009/4/8/medline SP - 205 EP - 12 JF - Clinical calcium JO - Clin Calcium VL - 19 IS - 2 N2 - Numerous experimental and clinical studies have recently addressed the underlying mechanisms in particular the marked increase in cardiovascular mortality in patients with CKD. Hyperphosphatemia is a major problem in these patients with advanced stage of CKD. Calcium carbonate became the most widely used phosphate binders ; however, increasing evidence now suggests that prolonged use of these agents increases the total body calcium load, induces adynamic bone, and potentially increases the risk of cardiovascular and soft tissue calcification. Sevelamer is the first phosphate-binding agent that is non-absorbed, calcium-free, and metal-free. To date, this agent has been shown to effectively control serum phosphorus levels in patients with CKD. It may also attenuate coronary and aortic calcification and has a number of other beneficial effects on lipid metabolism and inflammation among others. SN - 0917-5857 UR - https://www.unboundmedicine.com/medline/citation/19182360/[Management_of_hyperphosphatemia_ L2 - https://medlineplus.gov/kidneydiseases.html DB - PRIME DP - Unbound Medicine ER -